Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa.

Nanoscope Therapeutics Inc. is planning to submit a Biologics License Application (BLA) for MCO-010, a gene therapy for retinitis pigmentosa (RP), following a productive FDA meeting. RP often leads to severe vision loss and blindness, impacting patients' quality of life. The FDA's feedback has informed Nanoscope's BLA submission plan, offering a potential restorative option for RP patients. The company's commitment to advancing therapies for retinal degenerative diseases is evident in their progress with MCO-010 and other programs like Stargardt macular degeneration. [Extracted from the article]